# A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Study · id `cardio:ct-nct04153929` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04153929](<https://clinicaltrials.gov/study/NCT04153929>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04153929

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 413 participants.

## Technical summary

Registry record NCT04153929. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-30 (actual); primary completion 2021-10-08 (actual). Results posted on 2022-11-29.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 413 participants (enrolled count; ClinicalTrials.gov record NCT04153929, source copy `cardio:ctgov-nct04153929-2022-11-29`, retrieved 2026-10-26)
- Started: 2020-04-30 (actual) (ClinicalTrials.gov record NCT04153929, source copy `cardio:ctgov-nct04153929-2022-11-29`, retrieved 2026-10-26)
- Primary completion: 2021-10-08 (actual) (ClinicalTrials.gov record NCT04153929, source copy `cardio:ctgov-nct04153929-2022-11-29`, retrieved 2026-10-26)
- Completion: 2021-11-04 (actual) (ClinicalTrials.gov record NCT04153929, source copy `cardio:ctgov-nct04153929-2022-11-29`, retrieved 2026-10-26)
- Results first posted: 2022-11-29 (ClinicalTrials.gov record NCT04153929, source copy `cardio:ctgov-nct04153929-2022-11-29`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Canada; Czechia; Germany; Hungary; New Zealand; Poland; Puerto Rico; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT04153929, source copy `cardio:ctgov-nct04153929-2022-11-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04153929-2022-11-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): BI 456906
- Intervention (Drug): Placebo
- Intervention (Drug): Semaglutide
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial (`cardio:pubmed-38095657`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 509ce21145642ee587b6f91a9021bfe5bcb8cd2951e735149a0b6595cdf00013
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
